This activity will provide an evidence-based approach to diagnosing irritable bowel syndrome (IBS) with minimal testing. Diagnostic tests that facilitate a positive diagnosis of IBS and effective approaches for educating patients will be highlighted. The panel will spotlight diet changes and over-the-counter agents which are helpful first-line therapies. Evidence-based guidelines will identify the most effective and best tolerated prescription agents for IBS and chronic constipation patients.
Heartburn is a frequent complaint in primary care practices. The etiology is broad, from reflux to H. pylori infection and PUD. While many clinicians treat symptomatically, this may not lead to patient satisfaction. A recent network meta-analysis published in The BMJ, concluded that a ‘test and treat’ approach resulted in the lowest reports for patients to remain symptomatic at follow-up.
The degree to which early exposure to gluten-containing foods affects the risk of developing celiac disease is controversial. Join us as we discuss a recent Norwegian study suggesting that the timing of introduction of gluten in the diet may be less important than the amount of gluten in the diet at 18 months of age.
This presentation will use case-based scenarios to illustrate different patterns of liver test abnormalities. The faculty will discuss the difference between cholestatic versus hepatitis versus infiltrative liver diseases and their characteristic liver test patterns. You will learn about the workup of liver test abnormalities with subsequent supplemental serological testing, imaging, and in some cases, liver biopsy. After this session, you will know the difference between true “liver function tests,” tests of cholestasis, tests of inflammation, and tests of infiltration.
This activity will provide an evidence-based approach to the diagnosis and management of irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020 and they are subject to change as new information is published.
In this session Dr. Chopra, a world renowned hepatologist, thinker, inspirational speaker and bestselling author will simulate commonly posed curbside and email questions to a hepatologist from a primary care clinician. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 9, 2020, and they are subject to change as new information is published.
This session will review the geographical distribution of people at risk for developing celiac disease and populations that should undergo screening for celiac disease. The faculty will describe the changing presentations of celiac disease, review the gastroenterological and extraintestinal manifestations (such as irritable bowel disease), and emphasize the importance of a gluten free diet as an integral component to successful remission. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on Feb 9, 2020, and they are subject to change as new information is published.
Join this lecture for an overview of the pathophysiology, evaluation, and management of patients with nonalcoholic fatty liver disease. The faculty will review current concepts, disease progression, and therapeutics. You will learn about surgical treatments and their impact in patients with nonalcoholic steatohepatitis and obesity as well as the risk for hepatocellular carcinoma.
This talk will discuss the appropriate use of PPIs, including FDA indications and other accepted uses based on guidelines and systematic reviews. There will also be a brief review of the literature regarding issues of PPI safety. While many retrospective studies have raised concerns about various health conditions associated with PPI use, the quality of these studies need to be accounted for when considering the potential benefit that can be derived from these medications, even with long-term use. Finally, the faculty will provide a summary of “best practices."